


Diabetic foot infection: antimicrobial prescribing



Diabetic foot infection: antimicrobial prescribing

Mild infection: choice of antibiotic for adults aged 18 years and over

Antibiotic ¹	Dosage and course length ²
First choice oral antibiotic	
Flucloxacillin	500 mg to 1 g four times a day for 7 days ^{3,4}
Alternative oral antibiotics for penicillin allergy or if flucloxacillin unsuitable (guided by microbiological results when available)	
Clarithromycin	500 mg twice a day for 7 days ³
Erythromycin (in pregnancy)	500 mg four times a day for 7 days ³
Doxycycline	200 mg on first day, then 100 mg once a day (can be increased to 200 mg daily) for 7 days ³
<p>¹See BNF for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breast-feeding.</p> <p>²Oral doses are for immediate-release medicines.</p> <p>³A longer course (up to a further 7 days) may be needed based on clinical assessment. However, skin does take some time to return to normal, and full resolution of symptoms at 7 days is not expected.</p> <p>⁴The upper dose of 1 g four times a day would be off-label. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Good practice in prescribing and managing medicines and devices for further information.</p>	

When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

Diabetic foot infection: antimicrobial prescribing

Moderate or severe infection: choice of antibiotic for adults aged 18 years and over

Antibiotic ¹	Dosage ²	
First choice antibiotics (guided by microbiological results when available) ^{3,4,5} . In severe infection give IV for at least 48 hours (until stabilised). Course length is based on clinical assessment: minimum 7 days and up to 6 weeks for osteomyelitis (use oral antibiotics for prolonged treatment) ⁶		
Flucloxacillin with or without	1 g four times a day orally ⁷	or 1 to 2 g four times a day IV
Gentamicin ^{8,9} and/or	Initially 5 to 7 mg/kg once a day IV, subsequent doses adjusted according to serum gentamicin concentration	
Metronidazole	400 mg three times a day orally	or 500 mg three times a day IV
Co-amoxiclav with or without	500/125 mg three times a day orally	or 1.2 g three times a day IV
Gentamicin ^{8,9}	Initially 5 to 7 mg/kg once a day IV, subsequent doses adjusted according to serum gentamicin concentration	
Co-trimoxazole (in penicillin allergy) ^{9,10} with or without	960 mg twice a day orally	or 960 mg twice a day IV (can be increased to 1.44 g twice a day)
Gentamicin ^{8,9} and/or	Initially 5 to 7 mg/kg once a day IV, subsequent doses adjusted according to serum gentamicin concentration	
Metronidazole	400 mg three times a day orally	or 500 mg three times a day IV
Ceftriaxone with	2 g once a day IV	
Metronidazole	400 mg three times a day orally	or 500 mg three times a day IV
Additional antibiotic choices if <i>Pseudomonas aeruginosa</i> suspected or confirmed (guided by microbiological results when available) ^{3,4,5,11}		
Piperacillin with tazobactam	4.5 g three times a day IV (can be increased to 4.5 g four times a day)	
Clindamycin with	150 to 300 mg four times a day orally (can be increased to 450 mg four times a day)	or 600 mg to 2.7 g daily IV in two to four divided doses, increased if necessary in life-threatening infection to 4.8 g daily (maximum per dose 1.2 g)
Ciprofloxacin (consider safety issues ¹²) and/or	500 mg twice a day orally	or 400 mg two or three times a day IV
Gentamicin ^{8,9}	Initially 5 to 7 mg/kg once a day IV, subsequent doses adjusted according to serum gentamicin concentration	
Antibiotics to be added if MRSA infection suspected or confirmed (combination therapy with an antibiotic listed above) ^{4,5}		
Vancomycin ^{8,9}	15 to 20 mg/kg two or three times a day IV (maximum 2 g per dose), adjusted according to serum vancomycin concentration	
Teicoplanin ^{8,9}	Initially 6 mg/kg every 12 hours for three doses, then 6 mg/kg once a day IV	
Linezolid (if vancomycin or teicoplanin cannot be used; specialist use only) ⁹	600 mg twice a day orally	or 600 mg twice a day IV

¹See [BNF](#) for use and dosing in specific populations, for example, hepatic and renal impairment, pregnancy and breast-feeding, and administering IV (or, where appropriate, intramuscular) antibiotics.

²Oral doses are for immediate-release medicines.

³Give oral antibiotics first-line if the person can take oral medicines, and the severity of their condition does not require intravenous antibiotics.

⁴Review intravenous antibiotics by 48 hours and consider switching to oral antibiotics if possible.

⁵Other antibiotics may be appropriate based on microbiological results and specialist advice.

⁶Skin takes some time to return to normal, and full resolution of symptoms after a course of antibiotics is not expected. Review the need for continued antibiotics regularly.

⁷The dose of 1 g four times a day would be off-label. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Good practice in prescribing and managing medicines and devices](#) for further information.

⁸See [BNF](#) for information on therapeutic drug monitoring.

⁹See [BNF](#) for information on monitoring of patient parameters.

¹⁰Not licensed for diabetic foot infection, so use would be off label (see above).

¹¹These antibiotics may also be appropriate in other situations based on microbiological results and specialist advice.

¹²See [MHRA advice](#) for restrictions and precautions for using fluoroquinolone antibiotics due to very rare reports of disabling and potentially long-lasting or irreversible side effects (March 2019).